Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 20, 2010 Jordan DiPietro	Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment.
The Motley Fool June 15, 2011 Brian Orelli	Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story.
The Motley Fool December 31, 2007 Brian Lawler	Cephalon's Date With the FDA In the last day of the year, Cephalon announces that it has submitted another New Drug Application for oncology treatment Treanda. Expect to hear back from FDA on this priority review before the middle of 2008.
The Motley Fool September 28, 2011 Brian Orelli	One Step Closer to an FDA Decision Cell Therapeutics is still risky, though.
The Motley Fool September 15, 2010 Brian Orelli	Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out.
The Motley Fool August 29, 2006 Brian Lawler	More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note.
The Motley Fool December 11, 2007 Brian Orelli	Medicare Whacks Oncology Drugs Bad news for some pharmaceutical companies as Medicare announces it is reducing the reimbursement rate for two lymphoma drugs.
The Motley Fool September 29, 2010 Brian Orelli	Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers.
The Motley Fool November 22, 2011 Brian Orelli	This Spec Pharma Hopes Convenience Trumps All Spectrum Pharmaceuticals' Zevalin no longer requires a bioscan.
The Motley Fool June 27, 2008 Brian Orelli	The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers.
The Motley Fool December 31, 2008 Brian Orelli	Health Care's Golden Children The whole industry wasn't down this year.
The Motley Fool September 17, 2010 Luke Timmerman	Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders?
The Motley Fool July 1, 2011 Brian Orelli	What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug."
The Motley Fool December 20, 2011 Brian Orelli	What's Up With the Back-Slapping, Sequenom? Some sales numbers would be nice.
The Motley Fool December 31, 2011 David Williamson	2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here?
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool April 30, 2008 Brian Lawler	A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.
The Motley Fool May 9, 2011 Brian Orelli	Why Is Sequenom Up 20%? Investors appear to be overreacting.
The Motley Fool May 27, 2011 Brian Orelli	What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate.
The Motley Fool May 4, 2011 Brian Orelli	Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down.
The Motley Fool December 11, 2008 Brian Orelli	ASH Wrap-Up: Alphabet Soup and Drugs Let's take a look at the data that came out of the American Society of Hematology meeting regarding pharmaceutical companies' medications for blood diseases.
The Motley Fool July 30, 2010 Anand Chokkavelu	5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.
The Motley Fool November 30, 2010 Brian Orelli	Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers.
The Motley Fool December 9, 2011 David Williamson	1 Biotech Soars While Another Crashes Cell Therapeutics dilutes shareholders while SIGA squashes fears.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
The Motley Fool January 4, 2012 Brian Orelli	Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining.
The Motley Fool October 18, 2011 Brian Orelli	How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan.
The Motley Fool June 17, 2004 Brian Gorman	Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results.
Registered Rep. February 1, 2005 Bob Hirschfeld	Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street.
The Motley Fool January 5, 2011 Brian Orelli	Spectrum Pharma Jumps in With the Big Dogs Spectrum is developing biosimilars.
The Motley Fool October 19, 2010 Travis Hoium	Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri.
The Motley Fool June 3, 2010 Brian Orelli	The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development.
The Motley Fool September 24, 2008 Brian Orelli	100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in.
BusinessWeek May 28, 2009 Catherine Arnst	Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs.
The Motley Fool July 29, 2011 Sean Williams	Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling.
The Motley Fool February 8, 2005 Charly Travers	Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance.
The Motley Fool June 15, 2005 Brian Gorman	Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors.
The Motley Fool September 18, 2009 Brian Orelli	Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom.
The Motley Fool May 28, 2009 Robert Steyer	Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena.
The Motley Fool December 23, 2011 Selena Maranjian	3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick.
The Motley Fool July 13, 2011 David Williamson	Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of.
The Motley Fool April 30, 2009 Brian Orelli	How to Lose 75% of Your Company's Value Overnight Sequenom's shares sink 75% after the company said that four employees have been suspended because of "employee mishandling of R&D test data and results" for its revolutionary blood test for Down syndrome.
The Motley Fool October 14, 2010 Matt Koppenheffer	Cell Therapeutics' Shares Popped: What You Need to Know Shares of biopharma specialist Cell Therapeutics leapt more than 16% today on huge volume.
The Motley Fool June 5, 2008 Brian Orelli	Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry.
IndustryWeek November 1, 2001 Amy Kover	Survival Strategies As an ill-fated start-up now moving toward behemoth status, IDEC Pharmaceuticals is beating the odds in the biotechnology market...
The Motley Fool October 17, 2006 Brian Lawler	Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.
The Motley Fool September 18, 2006 Brian Lawler	Cell Therapeutics' New Mate The biopharmaceutical company removes some uncertainty by teaming up with Novartis. Investors, take note.